GNRH-A Goserelin

Phase 1Small molecule

PPraful Ravi, MB BCHir, MRCP

GNRH-A Goserelin is one of 30 small molecule programs targeting Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Ifex

BBaxter Healthcare Corporation

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Active, not recruiting·PPraful Ravi, MB BCHir, MRCP·Phase 1·NCT05617885·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GNRH-A Goserelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNRH-A Goserelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNRH-A Goserelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Praful Ravi, MB BCHir, MRCP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPraful Ravi, MB BCHir, MRCP

GNRH-A Goserelin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News